Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRXBiotechnology
+$0.07 today
- Market cap
- $417.57M
- Beta
- 1.48
- P/E (TTM)
- -8.5
- EPS (TTM)
- -$0.74
Volume 1.21M
Average 0.22M
EPRX Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 56.71M shares rose 58.9% year over year, ahead of the +27.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 9.2% from the prior quarter. Over 3 fiscal years it compounded at +27.5% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +58.9% holds above the trailing-twelve-month pace of +27.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 39.96M USD
- Year-over-year change
- +17.8%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.96M | +17.8% |
| FY2024 | 2024-12-31 | 33.93M | +40.5% |
| FY2023 | 2023-12-31 | 24.15M | — |
| FY2022 | 2022-12-31 | 19.29M | +35.4% |
| FY2021 | 2021-12-31 | 14.24M | — |
Weighted Avg Shares (Diluted) vs competitors
How EPRX compares with its peers on the latest reported figures
- EPRX's LTM Mar 2026 weighted avg shares (diluted) of 45.37M shares is the 4th highest of the 10 companies compared; the peer median is 38.39M shares.
- Its year-over-year change of +27.3% is the 4th highest of 9, against a peer median of +15.3%.
- Over three fiscal years its annual growth of +27.5% compares with a peer median of +43.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| FY2025 | 186.8M | +259.4% | +65.2% | |
| LTM Sep 2026 | 179.3M | +94.5% | +77.8% | |
| LTM Mar 2026 | 126.35M | +0.5% | +0.4% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | 45.37M | +27.3% | +27.5% |
| LTM Mar 2026 | 43.36M | +56.7% | +56.1% | |
| LTM Mar 2026 | 38.39M | +2.6% | +14.7% | |
| LTM Mar 2026 | 26.32M | +15.6% | +85.8% | |
| LTM Mar 2026 | 21.77M | +1.1% | +0.7% | |
| LTM Mar 2026 | 20.19M | — | — | |
| LTM Mar 2026 | 11.89M | +14.9% | +31.6% | |
| Peer median (excluding EPRX) | 38.39M | +15.3% | +43.9% | |
Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 112.38K | 0 | 0 | 163.47K | 331.89K |
| Gross Profit | (112.38K) | 0 | 0 | (163.47K) | (331.89K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.59M | 13.63M | 15.33M | 16.07M | 29.51M |
| Selling, General & Admin | 6.97M | 3.99M | 5.63M | 10.92M | 17.1M |
| Operating Expenses | 14.65M | 17.62M | 20.97M | 26.99M | 53.33M |
| Depreciation & Amortization | 87.47K | 147.89K | 117.1K | 171.6K | 331.89K |
| EBITDA | (17.22M) | (17.86M) | (20.78M) | (24.95M) | (53.33M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (14.65M) | (17.62M) | (20.97M) | (26.99M) | (53.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 51.55K | 431.8K | 649.75K | 1.16M | 1.41M |
| Interest Expense | 1.02M | 982.86K | 881.05K | 603.17K | 0 |
| Other Income / Expenses | (3.68M) | (1.37M) | (814.93K) | 1.26M | (212.94K) |
| Income Before Tax | (18.33M) | (18.99M) | (21.78M) | (25.73M) | (53.87M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 27.42K | 1.8K | 26.65K |
| Net Income | (18.03M) | (18.49M) | (21.25M) | (25.49M) | (53.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.63) | (0.96) | (0.88) | (0.76) | (1.05) |
| EPS (Diluted) | (1.63) | (0.96) | (0.88) | (0.76) | (1.05) |
| Weighted Avg Shares | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
| Weighted Avg Shares (Diluted) | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
Intrinsic Alpha fair value
Locked
Current Price
$6.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.